https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-growth-fiscal-q4-2026 BiopharmaWatch en 2026-10-26T17:00:00.000Z Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261026 BiopharmaWatch en 2026-10-26T15:57:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/LLY/lilly-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-26T15:19:00.000Z Lilly declares fourth-quarter 2026 dividend https://www.biopharmawatch.com/news/ZBH/comeback-club-joint-replacement-launch BiopharmaWatch en 2026-10-26T14:21:00.000Z Arthritis Foundation and Founding Sponsor Zimmer Biomet Announce New Community Celebrating Life After Joint Replacement and Inspiring Others to Act on Severe Joint Pain https://www.biopharmawatch.com/news/INCY/incyte-gastrointestinal-cancer-esmo-2026 BiopharmaWatch en 2026-10-26T13:45:00.000Z Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 https://www.biopharmawatch.com/news/CHRS/coherus-oncology-third-quarter-2026-results BiopharmaWatch en 2026-10-26T13:30:00.000Z Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/HSTM/healthstream-host-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-26T13:25:00.000Z HealthStream to Host Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/AKBA/u-s-renal-care-presents-analysis-voice-trial-demonstrating-favorable BiopharmaWatch en 2026-10-26T13:20:00.000Z U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week https://www.biopharmawatch.com/news/AKBA/us-renal-care-voice-trial-vadadustat-safety-outcomes BiopharmaWatch en 2026-10-26T13:20:00.000Z U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week https://www.biopharmawatch.com/news/NTHI/neonc-expands-brain-cancer-trial-500-patients BiopharmaWatch en 2026-10-26T13:19:00.000Z NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries https://www.biopharmawatch.com/news/LGVN/longeveron-elpis-ii-phase-2b-results-hlhs BiopharmaWatch en 2026-10-26T13:15:00.000Z Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) https://www.biopharmawatch.com/news/BMRN/biomarin-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-26T13:00:00.000Z BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET https://www.biopharmawatch.com/news/ABT/abbott-launches-oncodetect-mrd-test-cancer-detection BiopharmaWatch en 2026-10-26T13:00:00.000Z Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment https://www.biopharmawatch.com/news/SGRY/healthspan-partners-acquire-surgery-partners BiopharmaWatch en 2026-10-26T13:00:00.000Z HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform https://www.biopharmawatch.com/news/ALGN/align-technology-commits-1-million-aao-foundation BiopharmaWatch en 2026-10-26T13:00:00.000Z Align Technology Commits Additional $1 Million to the American Association of Orthodontists Foundation to Support the Next Generation of Orthodontic Educators and Leaders https://www.biopharmawatch.com/news/STLN/starling-oncology-q3-2026-earnings-release BiopharmaWatch en 2026-10-26T13:00:00.000Z Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/ACB/aurora-cannabis-curaleaf-application-dismissed BiopharmaWatch en 2026-10-26T12:47:00.000Z Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program https://www.biopharmawatch.com/news/AZTR/azitra-ex-vivo-study-atr-cosf-results BiopharmaWatch en 2026-10-26T12:45:00.000Z Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin https://www.biopharmawatch.com/news/DARE/dare-bioscience-dare-idds-podd-2026 BiopharmaWatch en 2026-10-26T12:32:00.000Z Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly https://www.biopharmawatch.com/news/BEAT/heartbeam-fda-total-product-life-cycle-advisory-program BiopharmaWatch en 2026-10-26T12:31:00.000Z HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-ingrezza-tardive-dyskinesia-analysis BiopharmaWatch en 2026-10-26T12:30:00.000Z Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-completion-treatment-fifth-cohort-ovarian-cancer-car BiopharmaWatch en 2026-10-26T12:30:00.000Z Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/DCTH/delcath-systems-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-26T12:30:00.000Z Delcath Systems to Host Third Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/SDGR/schrodinger-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261026 BiopharmaWatch en 2026-10-26T12:30:00.000Z Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NVCT/nuvectis-nxp200-phase-1b-study-results BiopharmaWatch en 2026-10-26T12:30:00.000Z Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas https://www.biopharmawatch.com/news/EQ/equillium-phase-1-trial-eq504-dosing BiopharmaWatch en 2026-10-26T12:30:00.000Z Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 https://www.biopharmawatch.com/news/SSII/ss-innovations-ss-mantra-telesurgery-october-2026 BiopharmaWatch en 2026-10-26T12:30:00.000Z SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-investor-conferences-nov-dec-2026 BiopharmaWatch en 2026-10-26T12:30:00.000Z Allogene Therapeutics Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-chemotherapy-resistant-cancer BiopharmaWatch en 2026-10-26T12:30:00.000Z Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability https://www.biopharmawatch.com/news/AVTR/avantor-appoints-new-cio BiopharmaWatch en 2026-10-26T12:05:00.000Z Avantor appoints new Chief Information Officer https://www.biopharmawatch.com/news/APVO/apvo-mipletamig-aml-stem-cell-transplant BiopharmaWatch en 2026-10-26T12:05:00.000Z Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-2026-financial-results-call BiopharmaWatch en 2026-10-26T12:01:00.000Z Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update https://www.biopharmawatch.com/news/HEPA/hepion-fda-feedback-gv104-fentanyl-cardiac-arrest BiopharmaWatch en 2026-10-26T12:01:00.000Z Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest https://www.biopharmawatch.com/news/ASPI/renergen-virginia-gas-project-stable-helium-production BiopharmaWatch en 2026-10-26T12:00:00.000Z ASP Isotopes Inc. Announces that Renergen Limited’s Virginia Gas Project has Achieved Stable Liquid Helium Production https://www.biopharmawatch.com/news/BSX/boston-scientific-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-26T12:00:00.000Z Boston Scientific to participate in Stifel's 2026 Healthcare Conference https://www.biopharmawatch.com/news/EVGN/evogene-participate-bio-europe-drug-discovery-chemistry BiopharmaWatch en 2026-10-26T12:00:00.000Z Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain https://www.biopharmawatch.com/news/VBIO/valion-bio-acquisition-interest-velocity-bioworks BiopharmaWatch en 2026-10-26T12:00:00.000Z Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-results-november-12 BiopharmaWatch en 2026-10-26T12:00:00.000Z Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/ATRC/atricure-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-26T12:00:00.000Z AtriCure to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CORT/corcept-phase-2-bella-trial-results BiopharmaWatch en 2026-10-26T12:00:00.000Z Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/CVM/cel-sci-phase-3-multikine-data-world-congress BiopharmaWatch en 2026-10-26T12:00:00.000Z CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival https://www.biopharmawatch.com/news/MIRM/mirum-positive-results-progress-study-atebrioz BiopharmaWatch en 2026-10-26T12:00:00.000Z Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-ceo-appointment BiopharmaWatch en 2026-10-26T12:00:00.000Z Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-celia-economides-cfo-appointment BiopharmaWatch en 2026-10-26T12:00:00.000Z Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer https://www.biopharmawatch.com/news/SLDB/solid-biosciences-orphan-designation-sgt-212-falcon-trial BiopharmaWatch en 2026-10-26T12:00:00.000Z Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia https://www.biopharmawatch.com/news/OPTH/optimi-health-launches-australia-subsidiary BiopharmaWatch en 2026-10-26T12:00:00.000Z Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity https://www.biopharmawatch.com/news/BIVI/biovie-present-data-bezisterim-long-covid-recover-tlc BiopharmaWatch en 2026-10-26T12:00:00.000Z BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-leadership-immunology-pipeline BiopharmaWatch en 2026-10-26T12:00:00.000Z Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline https://www.biopharmawatch.com/news/ASND/transcon-pth-improves-kidney-function-hypoparathyroidism BiopharmaWatch en 2026-10-26T12:00:00.000Z TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years https://www.biopharmawatch.com/news/SYK/stryker-acquisition-zurimed-shoulder-offering BiopharmaWatch en 2026-10-26T12:00:00.000Z Stryker completes acquisition of ZuriMED to enhance its shoulder offering https://www.biopharmawatch.com/news/GTBP/gt-biopharma-sitc-2026-presentation BiopharmaWatch en 2026-10-26T12:00:00.000Z GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/HIND/vyome-dr-shiladitya-sengupta-harvard-promotion BiopharmaWatch en 2026-10-26T12:00:00.000Z Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art26-12-pain-treatment-iasp-2026 BiopharmaWatch en 2026-10-26T11:55:00.000Z Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-data-esmo-2026 BiopharmaWatch en 2026-10-26T11:31:00.000Z TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 https://www.biopharmawatch.com/news/QUCY/quantum-cyber-invited-present-quantum-antenna-technology-quantumct-quantum-sensing BiopharmaWatch en 2026-10-26T11:30:00.000Z Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening https://www.biopharmawatch.com/news/QUCY/quantum-cyber-presents-antenna-technology-quantumct-convening BiopharmaWatch en 2026-10-26T11:30:00.000Z Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening https://www.biopharmawatch.com/news/FEED/envue-medical-shareholder-letter-october-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z ENvue Medical Issues Letter to Shareholders https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-ifx-2-0-keytruda-mcc-study-data BiopharmaWatch en 2026-10-26T11:30:00.000Z TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma https://www.biopharmawatch.com/news/BHVN/biohaven-oral-presentation-asn-kidney-week-2026-spotlights-bhv-1420 BiopharmaWatch en 2026-10-26T11:30:00.000Z Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1420-asn-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy https://www.biopharmawatch.com/news/CGC/canopy-growth-2026-annual-meeting-results BiopharmaWatch en 2026-10-26T11:30:00.000Z Canopy Growth Announces Results of 2026 Annual General and Special Meeting of Shareholders https://www.biopharmawatch.com/news/DAVI/davion-healthcare-acquisition-humaskan-medical-technology BiopharmaWatch en 2026-10-26T11:30:00.000Z Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP https://www.biopharmawatch.com/news/BWAY/brainsway-expands-insurance-coverage-deep-tms-ocd BiopharmaWatch en 2026-10-26T11:30:00.000Z BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives https://www.biopharmawatch.com/news/MDCX/medicus-pharma-regains-nasdaq-compliance BiopharmaWatch en 2026-10-26T11:30:00.000Z Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-first-patient-dosed-xtx501-trial BiopharmaWatch en 2026-10-26T11:30:00.000Z Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC https://www.biopharmawatch.com/news/IMRX/immuneering-phase-3-mapkeeper-301-trial-esmo-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 https://www.biopharmawatch.com/news/MGNX/macrogenics-positive-phase-2-linnet-results-lorigerlimab BiopharmaWatch en 2026-10-26T11:06:00.000Z MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-neurotechnology-ai-devices-southeast-asia BiopharmaWatch en 2026-10-26T11:00:00.000Z Healthcare Triangle Enters Neurotechnology AI Devices and Solutions for Southeast Asia https://www.biopharmawatch.com/news/CANF/can-fite-phase-iia-namodenoson-esmo-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 https://www.biopharmawatch.com/news/CANF/can-fite-phase-iia-namodenoson-pancreatic-cancer-esmo-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 https://www.biopharmawatch.com/news/CGEN/compugen-release-q3-2026-results-november-9 BiopharmaWatch en 2026-10-26T11:00:00.000Z Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/CGEN/compugen-q3-2026-results-release BiopharmaWatch en 2026-10-26T11:00:00.000Z Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/REGN/regeneron-barda-agreement-inmazeb-ebola-treatment BiopharmaWatch en 2026-10-26T11:00:00.000Z Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness https://www.biopharmawatch.com/news/REGN/regeneron-barda-agreement-ebola-treatment-inmazeb BiopharmaWatch en 2026-10-26T11:00:00.000Z Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness https://www.biopharmawatch.com/news/NTRA/natera-asn-kidney-week-2026-genetic-testing-renasight BiopharmaWatch en 2026-10-26T11:00:00.000Z Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™ https://www.biopharmawatch.com/news/ENTA/enanta-resolve-phase-2b-3-zelicapavir-rsv BiopharmaWatch en 2026-10-26T11:00:00.000Z Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) https://www.biopharmawatch.com/news/IMNM/immunome-varegacestat-esmo-2026-data BiopharmaWatch en 2026-10-26T11:00:00.000Z Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 https://www.biopharmawatch.com/news/GMAB/genmab-phase-2-data-petosemtamab-pembrolizumab-hnscc BiopharmaWatch en 2026-10-26T11:00:00.000Z Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-lupus-nephritis-asn-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 https://www.biopharmawatch.com/news/PLUR/pluri-zeo-partner-us-manufacturing-regenerative-medicine BiopharmaWatch en 2026-10-26T11:00:00.000Z Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-orka-001-results-everlast-b-trial BiopharmaWatch en 2026-10-26T11:00:00.000Z Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis https://www.biopharmawatch.com/news/ELDN/eledon-phase-2-bestow-trial-data-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting https://www.biopharmawatch.com/news/HROW/harrow-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-26T11:00:00.000Z Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-26T11:00:00.000Z Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-esmo-2026-data BiopharmaWatch en 2026-10-26T11:00:00.000Z Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q3-2026-results-call BiopharmaWatch en 2026-10-26T11:00:00.000Z Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/SNDX/syndax-announces-q3-2026-results-conference-call BiopharmaWatch en 2026-10-26T11:00:00.000Z Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 https://www.biopharmawatch.com/news/PLX/protalix-bio-present-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-26T10:50:00.000Z Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-eik1001-esmo-2026 BiopharmaWatch en 2026-10-26T10:00:00.000Z Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MDLN/medline-10-years-partnership-wrap-responsible-manufacturing BiopharmaWatch en 2026-10-26T09:00:00.000Z Medline Celebrates 10 Years of Partnership with WRAP, Advancing Responsible Manufacturing https://www.biopharmawatch.com/news/BNTX/biontech-dualitybio-dynasty-breast02-trial-results BiopharmaWatch en 2026-10-26T09:00:00.000Z BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer https://www.biopharmawatch.com/news/HCM/hutchmed-sanovo-phase-iii-orpathys-tagrisso-lung-cancer BiopharmaWatch en 2026-10-26T08:30:00.000Z HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/YI/111-inc-appoints-independent-advisors-special-committee BiopharmaWatch en 2026-10-26T08:00:00.000Z 111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-fda-litigation-update BiopharmaWatch en 2026-10-26T08:00:00.000Z Phathom Pharmaceuticals Provides Update on FDA Litigation https://www.biopharmawatch.com/news/BMY/iza-bren-doubles-pfs-egfr-nsclc-study BiopharmaWatch en 2026-10-26T07:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study https://www.biopharmawatch.com/news/BMY/iza-bren-doubles-pfs-nsclc-study BiopharmaWatch en 2026-10-26T07:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-26 BiopharmaWatch en 2026-10-26T07:15:24.500Z IGALMI PDUFA for Agitation: Biotech Catalysts Oct 26, 2026 https://www.biopharmawatch.com/news/HCM/hutchmed-saffron-phase-iii-trial-results BiopharmaWatch en 2026-10-26T00:00:00.000Z HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-host-conference-call-report-week-16-data-orka BiopharmaWatch en 2026-10-25T16:00:00.000Z Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-advanced-biliary-tract-cancer BiopharmaWatch en 2026-10-25T15:52:00.000Z Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-amivantamab-hyaluronidase-lpuj-combination-demonstrates-77-overall BiopharmaWatch en 2026-10-25T13:45:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-head-neck-cancer-response-rate BiopharmaWatch en 2026-10-25T13:45:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer https://www.biopharmawatch.com/news/AVBP/arrivent-phase-1-data-cdh17-targeted-adc-arr-217 BiopharmaWatch en 2026-10-25T13:00:00.000Z ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 https://www.biopharmawatch.com/news/AMRN/amarin-update-phase-3-epa-metastasis-trial-emt2 BiopharmaWatch en 2026-10-25T12:11:00.000Z Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) https://www.biopharmawatch.com/news/AGEN/agenus-phase-2-results-neoasiss-study BiopharmaWatch en 2026-10-25T11:00:00.000Z Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 https://www.biopharmawatch.com/news/GMAB/genmab-phase-2-study-petosemtamab-colorectal-cancer BiopharmaWatch en 2026-10-25T11:00:00.000Z Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-givastomig-phase-1b-data-esmo-2026 BiopharmaWatch en 2026-10-25T11:00:00.000Z NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-survival-benefit-cscc BiopharmaWatch en 2026-10-25T09:15:00.000Z Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) https://www.biopharmawatch.com/news/XNCR/xencor-phase-1-xmab819-clear-cell-renal-cancer BiopharmaWatch en 2026-10-25T08:35:00.000Z Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors https://www.biopharmawatch.com/news/LLY/lilly-olomorasib-esmo-2026-data BiopharmaWatch en 2026-10-25T07:30:00.000Z New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer https://www.biopharmawatch.com/news/JNJ/jnj-6143-prostate-cancer-phase-1-results BiopharmaWatch en 2026-10-25T07:30:00.000Z Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule https://www.biopharmawatch.com/news/BNTX/biontech-bristol-myers-squibb-pumitamig-phase-2-data BiopharmaWatch en 2026-10-25T07:30:00.000Z BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy https://www.biopharmawatch.com/news/CLYM/climb-bio-budoprutug-phase-2-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-24T23:30:00.000Z Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026